{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:05:38Z","timestamp":1784718338737,"version":"3.55.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000996","name":"Australian Department of Foreign Affairs and Trade","doi-asserted-by":"publisher","award":["76820"],"award-info":[{"award-number":["76820"]}],"id":[{"id":"10.13039\/501100000996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunogenicity studies of booster doses of COVID-19 vaccines from Pacific Island countries are limited. A prospective cohort study was conducted amongst healthcare workers in Fiji to assess antibody neutralization capacity against ancestral, Delta, and Omicron (BA.2) variants following high force of infection from Delta during administration of primary dose schedules. Findings showed high baseline neutralization prior to heterologous booster vaccinations and enduring protective neutralization against all 3 variants of SARS-CoV-2 at 6 months following booster receipt. Limited benefit from third doses in this population emphasizes the need for pragmatic vaccination strategies guided by local disease contexts.<\/jats:p>","DOI":"10.1093\/infdis\/jiag363","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:46:45Z","timestamp":1784116005000},"source":"Crossref","is-referenced-by-count":0,"title":["Neutralization Capacity Against SARS-CoV-2 Ancestral, Delta, and Omicron Variants Before and After Heterologous Booster Vaccination in Fijian Healthcare Workers"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-3510","authenticated-orcid":false,"given":"Anaseini","family":"Ratu","sequence":"first","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]},{"name":"National Centre for Epidemiology and Population Health, Australian National University , Canberra ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1346-838X","authenticated-orcid":false,"given":"Isireli","family":"Rabukawaqa","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-7635","authenticated-orcid":false,"given":"Reuben","family":"McGregor","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland , Auckland ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Sassen","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Cagi","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitione","family":"Veitogavi","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]},{"name":"Otago Global Health Institute, University of Otago , Dunedin ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venina","family":"Naigulevu","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reapi","family":"Seru","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luse","family":"Lauci","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Ramiah","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland , Auckland ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren H","family":"Carlton","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland , Auckland ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Singh","sequence":"additional","affiliation":[{"name":"National Public Health Laboratory, Fiji Centre for Disease Control , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litiana","family":"Volavola","sequence":"additional","affiliation":[{"name":"Department of Family Health, Fiji Ministry of Health and Medical Services , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-3567","authenticated-orcid":false,"given":"Rachel","family":"Devi","sequence":"additional","affiliation":[{"name":"Department of Family Health, Fiji Ministry of Health and Medical Services , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Wilson","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-637X","authenticated-orcid":false,"given":"Nicole J","family":"Moreland","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland , Auckland ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C","family":"Hill","sequence":"additional","affiliation":[{"name":"Communicable Diseases Research Centre, Fiji Institute of Pacific Health Research, Fiji National University , Suva ,","place":["Fiji"]},{"name":"Otago Global Health Institute, University of Otago , Dunedin ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2026072206514914700_jiag363-B1","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. Reply","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"2026072206514914700_jiag363-B2","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"2026072206514914700_jiag363-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2023.2143347","article-title":"Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic","volume":"22","author":"Solante","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"2026072206514914700_jiag363-B4","doi-asserted-by":"crossref","first-page":"e1004397","DOI":"10.1371\/journal.pmed.1004397","article-title":"Levels and functionality of Pacific Islanders\u2019 hybrid humoral immune response to BNT162b2 vaccination and Delta\/Omicron infection: a cohort study in New Caledonia","volume":"21","author":"Inizan","year":"2024","journal-title":"PLoS Med"},{"key":"2026072206514914700_jiag363-B5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"2026072206514914700_jiag363-B6","doi-asserted-by":"crossref","first-page":"126482","DOI":"10.1016\/j.vaccine.2024.126482","article-title":"The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: impact of vaccination and infection","volume":"42","author":"McGregor","year":"2024","journal-title":"Vaccine"},{"key":"2026072206514914700_jiag363-B7","volume-title":"Country case study Fiji\u2014containing, mitigating, and responding to COVID-19: knowledge generation and exchange, preparedness, and response (March 2020 to June 2022)","author":"Wilson","year":"2023"},{"key":"2026072206514914700_jiag363-B8","unstructured":"R Core Team\n          . R: a language and environment for statistical computing (Version 4.5.1). Vienna, Austria: R Foundation for Statistical Computing, 2025. https:\/\/www.r-project.org\/. Accessed 21 July 2025."},{"key":"2026072206514914700_jiag363-B9","unstructured":"R Studio Team\n          . RStudio: integrated development environment for R (Version 2025.08.0). Boston, USA: Posit Software, PBC, 2025. https:\/\/posit.co. Accessed 21 July 2025."},{"key":"2026072206514914700_jiag363-B10","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"Ggplot2: elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"2026072206514914700_jiag363-B11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination","volume":"600","author":"Pozzetto","year":"2021","journal-title":"Nature"},{"key":"2026072206514914700_jiag363-B12","doi-asserted-by":"crossref","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine\u2013induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026072206514914700_jiag363-B13","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.xcrm.2022.100679","article-title":"Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant","volume":"3","author":"Lyke","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026072206514914700_jiag363-B14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3201\/eid2901.221514","article-title":"Rapid SARS-CoV-2 seroprevalence survey in central and western divisions of Fiji, 2021","volume":"29","author":"Curtis","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"2026072206514914700_jiag363-B15","doi-asserted-by":"crossref","first-page":"100249","DOI":"10.1016\/j.lanepe.2021.100249","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic COVID-19 infection in Sweden: a nationwide cohort study","volume":"11","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Reg Health Eur"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag363\/69150118\/jiag363.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag363\/69150118\/jiag363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:51:54Z","timestamp":1784717514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag363\/8736408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag363","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"jiag363"}}